| Literature DB >> 34450028 |
Todd Logan1, Matthew J Simon1, Anil Rana1, Gerald M Cherf1, Ankita Srivastava1, Sonnet S Davis1, Ray Lieh Yoon Low1, Chi-Lu Chiu1, Meng Fang1, Fen Huang1, Akhil Bhalla1, Ceyda Llapashtica1, Rachel Prorok1, Michelle E Pizzo1, Meredith E K Calvert1, Elizabeth W Sun1, Jennifer Hsiao-Nakamoto1, Yashas Rajendra1, Katrina W Lexa1, Devendra B Srivastava1, Bettina van Lengerich1, Junhua Wang1, Yaneth Robles-Colmenares1, Do Jin Kim1, Joseph Duque1, Melina Lenser1, Timothy K Earr1, Hoang Nguyen1, Roni Chau1, Buyankhishig Tsogtbaatar1, Ritesh Ravi1, Lukas L Skuja1, Hilda Solanoy1, Howard J Rosen2, Bradley F Boeve3, Adam L Boxer2, Hilary W Heuer2, Mark S Dennis1, Mihalis S Kariolis1, Kathryn M Monroe1, Laralynne Przybyla1, Pascal E Sanchez1, Rene Meisner1, Dolores Diaz1, Kirk R Henne1, Ryan J Watts1, Anastasia G Henry1, Kannan Gunasekaran1, Giuseppe Astarita4, Jung H Suh1, Joseph W Lewcock1, Sarah L DeVos5, Gilbert Di Paolo6.
Abstract
GRN mutations cause frontotemporal dementia (GRN-FTD) due to deficiency in progranulin (PGRN), a lysosomal and secreted protein with unclear function. Here, we found that Grn-/- mice exhibit a global deficiency in bis(monoacylglycero)phosphate (BMP), an endolysosomal phospholipid we identified as a pH-dependent PGRN interactor as well as a redox-sensitive enhancer of lysosomal proteolysis and lipolysis. Grn-/- brains also showed an age-dependent, secondary storage of glucocerebrosidase substrate glucosylsphingosine. We investigated a protein replacement strategy by engineering protein transport vehicle (PTV):PGRN-a recombinant protein linking PGRN to a modified Fc domain that binds human transferrin receptor for enhanced CNS biodistribution. PTV:PGRN rescued various Grn-/- phenotypes in primary murine macrophages and human iPSC-derived microglia, including oxidative stress, lysosomal dysfunction, and endomembrane damage. Peripherally delivered PTV:PGRN corrected levels of BMP, glucosylsphingosine, and disease pathology in Grn-/- CNS, including microgliosis, lipofuscinosis, and neuronal damage. PTV:PGRN thus represents a potential biotherapeutic for GRN-FTD.Entities:
Keywords: GBA; LBPA; galectin-3; lipidomics; lipids; lipofuscin; lysobisphosphatidic acid; lysosome; metabolomics; neurodegenerative disease
Mesh:
Substances:
Year: 2021 PMID: 34450028 PMCID: PMC8489356 DOI: 10.1016/j.cell.2021.08.002
Source DB: PubMed Journal: Cell ISSN: 0092-8674 Impact factor: 66.850